BMRN (Biomarin Pharmaceutical) Buyback Yield % : 0.00 (As of Apr. 23, 2025)

View and export this data going back to 1999. Start your Free Trial

What is Biomarin Pharmaceutical Buyback Yield %?

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Biomarin Pharmaceutical's current buyback yield was 0.00%.

Biomarin Pharmaceutical Buyback Yield % Historical Data

The historical data trend for Biomarin Pharmaceutical's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Buyback Yield % Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

Get a 7-Day Free Trial

0.31

Biomarin Pharmaceutical Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Buyback Yield %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Biomarin Pharmaceutical's Buyback Yield %

For the Biotechnology subindustry, Biomarin Pharmaceutical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomarin Pharmaceutical's Buyback Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Buyback Yield % falls into.

Save Embed

;

Save Embed

;

Biomarin Pharmaceutical Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Biomarin Pharmaceutical's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	0)	/	12538.72053
	=	0.00%

Biomarin Pharmaceutical's annualized Buyback Yield for the quarter that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (0	+	0)		/	12538.72053
	=	0.00%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Biomarin Pharmaceutical Buyback Yield % Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Buyback Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biomarin Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (NAS:BMRN) » Definitions » Buyback Yield %

Comparable Companies

Traded in Other Exchanges

BMRN:Mexico 1BMRN:Italy 0HNC:UK BM8:Germany BM8:Germany B1MR34:Brazil BMRN:Austria

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

https://www.biomarin.com

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Executives

Erin Burkhart	officer: GVP, Chief Accounting Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Charles Greg Guyer	officer: EVP, Chief Technical Officer	C/O BIOMARIN PHARMACEUTICAL INC., 770 LINDARO ST., SAN RAFAEL CA 94901
Brian Mueller	officer: EVP, Chief Financial Officer	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
George Eric Davis	officer: VP, General Counsel	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Jean Jacques Bienaime	director, officer: Chief Executive Officer	925 PAGE MILL ROAD, PALO ALTO CA 94304
Jeffrey Robert Ajer	officer: EVP, Chief Commercial Officer	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Henry J Fuchs	officer: Chief Medical Officer	C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949
Mark J Alles	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elizabeth M Anderson	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Maykin Ho	director	C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
V Bryan Lawlis	director
Richard A Meier	director	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Dennis Slamon	director	770 LINDARO STREET, SAN RAFAEL CA 94901
Michael G Grey	director	C/O SGX PHARMACEUTICALS, INC., 10505 ROSELLE STREET, SAN DIEGO CA 92121
Pyott David E I	director	C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612